Big Pharma Goes East to Test Drugs

Johnson & Johnson division under scrutiny for manufacturing practices

(NEWSER) - After multiple drug recalls and an FDA safety probe, federal authorities are taking control of three Tylenol plants, CNNMoney reports. The plants, run by Johnson & Johnson’s McNeil division, are in trouble for dodging federal manufacturing rules; now, the company has agreed to let the FDA supervise the three—two in Pennsylvania and one in Puerto Rico—a decision that effectively wards off a threatened FDA lawsuit. The agreement, a so-called "consent decree," is subject to a Pennsylvania judge’s approval. More»

(NEWSER) - Federal regulators have consistently looked away as Big Pharma and other manufacturers poured at least 271 million pounds of drugs into waterways that supply US drinking water, the AP reports. Records kept unintentionally by the FDA and EPA show that 22 compounds, some considered dangerous by scientists, have leaked into America's water supply. But drug-makers say they're in compliance with federal laws—and officials agree. More»

Future drugs could boost job, classroom performance

(NEWSER) - Healthy adults should be able to take brain-boosting drugs for a competitive advantage at work or on an exam, researchers say in a provocative paper. Seven authors say ethical questions about cognitive-enhancement pills are both warranted and imminent, and that such medicinal aid is no less moral than caffeine consumption, the San Francisco Chronicle reports. More»

Edited info could mislead those prescribing meds

(NEWSER) - Pharmaceutical companies aren't as upfront with doctors as they are with the government about their new products, a study finds. Though drug companies must provide the FDA with all of the data from clinical trials, related papers published in medical journals were found to omit info from 20% of the trials, and were often presented with a favorable twist, Wired reports. More»

Drug Makers See Future in New Markets

(NEWSER) - The pharmaceutical industry is turning away from the US shores that helped fill its pockets and toward the developing world, the Economist reports. Massive growth has made markets like India and China too attractive to ignore, despite lower income levels and weaker patent laws. And many companies fear Barack Obama's health-care plans will mean major price cuts. More»